Evidence map›Paper›PMID 27874871›Full record

ArticleNature chemistry2016

Mass spectrometry captures off-target drug binding and provides mechanistic insights into the human metalloprotease ZMPSTE24.

Shahid Mehmood, Julien Marcoux, Joseph Gault, Andrew Quigley, Susan Michaelis, Stephen G Young, Elisabeth P Carpenter, Carol V Robinson

Open access · greenAbstract read
In one paragraph

Article in Nature chemistry, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
6.3field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 63 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Native Mass Spectrometry of Iron-Sulfur Proteins.Methods in molecular biology (Clifton, N.J.) · 2021
    Article
  10. Article
  11. Review
  12. Review
  13. Assembly and regulation of the chlorhexidine-specific efflux pump AceI.Proceedings of the National Academy of Sciences of the United States of America · 2020
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Shahid MehmoodDepartment of Chemistry, University of Oxford, South Parks Road, Oxford OX1 3QZ, UK.
Julien MarcouxDepartment of Chemistry, University of Oxford, South Parks Road, Oxford OX1 3QZ, UK.
Joseph GaultDepartment of Chemistry, University of Oxford, South Parks Road, Oxford OX1 3QZ, UK.ORCID 0000-0001-7686-2983
Andrew QuigleyStructural Genomics Consortium, University of Oxford, Old Road Campus Research Building, Roosevelt Drive, Oxford OX3 7DQ, UK.
Susan MichaelisDepartment of Cell Biology, The Johns Hopkins School of Medicine, Baltimore, Maryland 21205, USA.
Stephen G YoungDepartments of Medicine and Human Genetics, David Geffen School of Medicine, University of California, Los Angeles, California 90095, USA.
Elisabeth P CarpenterStructural Genomics Consortium, University of Oxford, Old Road Campus Research Building, Roosevelt Drive, Oxford OX3 7DQ, UK.
Carol V RobinsonDepartment of Chemistry, University of Oxford, South Parks Road, Oxford OX1 3QZ, UK.
University of Oxford · GBJohns Hopkins University · USUniversity of California, Los Angeles · US

Funding

The integral membrane protease ZMPSTE24, lamin A processing, and progeriaR01GM041223 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI MICHAELIS, SUSAN D. · 1989 to 2017
$5.0M
CaaX Protein Processing and Human DiseaseR01AG035626 · NIA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI YOUNG, STEPHEN G. · 2009 to 2013
$2.0M
ZMPSTE24, HIV treatment regimens, and atherosclerotic heart diseaseR01HL126551 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI YOUNG, STEPHEN G. · 2014 to 2017
$1.8M
Medical Research Council G1000819Medical Research Council MR/L017458/1Medical Research Council MR/N020413/1NHLBI NIH HHS R01 HL126551NIA NIH HHS R01 AG035626NIGMS NIH HHS R01 GM041223Wellcome Trust
6 · The paper itself

Abstract

Off-target binding of hydrophobic drugs can lead to unwanted side effects, either through specific or non-specific binding to unintended membrane protein targets. However, distinguishing the binding of drugs to membrane proteins from that of detergents, lipids and cofactors is challenging. Here, we use high-resolution mass spectrometry to study the effects of HIV protease inhibitors on the human zinc metalloprotease ZMPSTE24. This intramembrane protease plays a major role in converting prelamin A to mature lamin A. We monitored the proteolysis of farnesylated prelamin A peptide by ZMPSTE24 and unexpectedly found retention of the C-terminal peptide product with the enzyme. We also resolved binding of zinc, lipids and HIV protease inhibitors and showed that drug binding blocked prelamin A peptide cleavage and conferred stability to ZMPSTE24. Our results not only have relevance for the progeria-like side effects of certain HIV protease inhibitor drugs, but also highlight new approaches for documenting off-target drug binding.

Indexed as

HIV Protease InhibitorsHumansLamin Type ALipidsMass SpectrometryMembrane ProteinsMetalloendopeptidasesPharmaceutical PreparationsProtein BindingProtein PrenylationSubstrate SpecificityZincHIV Protease InhibitorsLamin Type ALipidsMembrane ProteinsMetalloendopeptidasesPharmaceutical Preparationsprelamin AZincZMPSTE24 protein, human

Identifiers

PMID27874871
PMCPMC5123592
OpenAlexW2514203454

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.